

Joy C. Hsu, Ph.D.

Dear ISoP Members,



I am an active member of the pharmacometrics community, and I have been a member of ISoP since its inception. I served on ACoP's Scientific Programming Committee from 2014 through 2018, and I had the privilege to be the Chair-Elect in 2017 and then Chair of the Scientific Programming Committee in 2018 for ACoP9. While in these roles to help shape the scientific programs for ACoP, I have been inspired by the many high quality proposals and diverse topics submitted by fellow members in our society. In addition, I also served as an ACoP abstract reviewer from 2011-2019. Currently, I am

part of the Scientific Expertise and Innovation Working Group, one of the core area under ISoP's Five-Year Strategic Plan, working to encourage continuous advancement and innovation in pharmacometrics.

I did my Ph.D. study in Biomedical Engineering with Dr. David D'Argenio at University of Southern California. Prior to my Ph.D., I received a M.S. in Regulatory Science from the University of Southern California and a B.S. in Biochemistry and Molecular Biology from University of California, Berkeley. I have been working for Roche/Genentech for 11 years as a Pharmacometrician and also as a Clinical Pharmacologist, and I am on the Steering Committee of the Roche Advanced Analytics Network. My experience focuses on clinical development in oncology, inflammation, infectious diseases, ophthalmology, rare diseases, and metabolism, from entry-into-human through Phase IV. I have also been fortunate to have the opportunity to support the filings and approvals of many molecules globally, helping to bring treatment to patients, which is the most rewarding part of my job.

Dr. D'Argenio's vision and his passion to shape the pharmacometrics community has a huge influence on me in giving back to our community. I am very passionate about bringing people together with different areas of expertise, such as statisticians, mathematicians, engineers, programmers, pharmacologists, clinicians, and regulators. I believe that strong collaboration and synergies from experts in different areas is key for pushing the boundaries of pharmacometrics in this rapidly changing field. If elected to the ISoP Board of Directors, I will further promote and expand the collaborations and dialogues among experts in different fields with different skill sets in the global pharmacometrics community and beyond. I will also further promote and champion the use of model-informed drug development together with all of you.